The $28 million verdict is the first trial loss related to Xarelto. Federal court has found in favor of the defendants three previous times. Bayer’s issued statement said the company did not believe that there was any basis for the verdict and that they planned to appeal.
Janssen Pharmaceuticals, owned by Johnson & Johnson, stated they planned to appeal because of the FDA’s belief that Xarelto is safe and the results of their own scientific studies.
